Amgen Inc
$ 332.93
-0.31%
26 Dec - close price
- Market Cap 179,276,349,000 USD
- Current Price $ 332.93
- High / Low $ 333.98 / 330.85
- Stock P/E 25.77
- Book Value 17.86
- EPS 12.92
- Next Earning Report 2026-02-03
- Dividend Per Share $9.39
- Dividend Yield 2.81 %
- Next Dividend Date 2026-03-06
- ROA 0.08 %
- ROE 0.82 %
- 52 Week High 346.38
- 52 Week Low 248.95
About
Amgen Inc. is a leading multinational biopharmaceutical company headquartered in Thousand Oaks, California, recognized for its pioneering therapies developed through recombinant DNA technology. The company focuses on key therapeutic areas including oncology, nephrology, and inflammation, utilizing its deep expertise in molecular biology to create and commercialize innovative biologic products that significantly improve patient outcomes. With a comprehensive drug pipeline and a strong foothold in the biotechnology landscape, Amgen is dedicated to addressing global unmet medical needs while striving to enhance the quality of life for patients across the globe. Its commitment to research and development positions Amgen as a critical player in advancing medical science and improving health outcomes worldwide.
Analyst Target Price
$325.88
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-05 | 2025-05-01 | 2025-02-04 | 2024-10-30 | 2024-08-06 | 2024-05-02 | 2024-02-06 | 2023-10-31 | 2023-08-03 | 2023-04-27 | 2023-01-31 |
| Reported EPS | 5.64 | 6.02 | 4.9 | 5.31 | 5.58 | 4.97 | 3.96 | 4.71 | 4.96 | 5 | 3.98 | 4.09 |
| Estimated EPS | 5.02 | 5.28 | 4.26 | 5.08 | 5.11 | 5.01 | 3.87 | 4.61 | 4.67 | 4.49 | 3.85 | 4.1 |
| Surprise | 0.62 | 0.74 | 0.64 | 0.23 | 0.47 | -0.04 | 0.09 | 0.1 | 0.29 | 0.51 | 0.13 | -0.01 |
| Surprise Percentage | 12.3506% | 14.0152% | 15.0235% | 4.5276% | 9.1977% | -0.7984% | 2.3256% | 2.1692% | 6.2099% | 11.3586% | 3.3766% | -0.2439% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 4.74 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-06 | 2025-12-12 | 2025-09-12 | 2025-06-06 | 2025-03-07 | 2024-12-09 | 2024-09-06 | 2024-06-07 | 2024-03-07 | 2023-12-08 |
| Amount | $2.52 | $2.38 | $2.38 | $2.38 | $2.38 | $2.25 | $2.25 | $2.25 | $2.25 | $2.13 |
Next Dividend Records
| Dividend per share (year): | $9.39 |
| Dividend Yield | 2.81% |
| Next Dividend Date | 2026-03-06 |
| Ex-Dividend Date | 2026-02-13 |
Recent News: AMGN
2025-12-28 12:55:44
Valley National Advisers Inc. significantly increased its stake in UnitedHealth Group (UNH) by 592.5%, purchasing 6,375 shares to hold a total of 7,451 shares valued at approximately $2.57 million. Several other major institutional investors, including Norges Bank and Berkshire Hathaway, also hold substantial positions in UNH, bringing total institutional ownership to 87.86%. Analysts generally rate UNH as "Hold" with an average price target of $385.54, and the company recently beat EPS expectations and announced a quarterly dividend of $2.21 per share.
2025-12-27 12:40:42
Meyer Handelman Co. recently reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0%, selling 3,881 shares but still holding 124,913 shares valued at around $35.25 million, making Amgen its 28th largest holding. Amgen has demonstrated strong financial performance, beating quarterly earnings expectations and raising its quarterly dividend. The company also maintains a "Moderate Buy" consensus rating from analysts with a target price of $332.85.
2025-12-27 10:25:53
Carnegie Investment Counsel significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) during Q3, now holding 107,260 shares valued at $30.27 million. This move comes as Amgen reported strong Q3 earnings, beating estimates with $5.64 EPS, and analysts maintain a "Moderate Buy" consensus with an average price target of $332.85. The company also raised its quarterly dividend to $2.52 per share, despite recent insider selling activity.
2025-12-27 00:08:46
The iShares Biotechnology ETF (IBB) is a prominent smart beta ETF in the Health Care sector, offering broad exposure to biotechnology and pharmaceutical companies. With over $8.68 billion in assets and a 0.44% expense ratio, it tracks the Nasdaq Biotechnology Index. While considered a high-risk choice due to its volatility, it has shown strong performance, gaining approximately 31.33% in the past year.
2025-12-26 12:07:25
Pacer Advisors Inc. reduced its stake in Amgen Inc. by 8.8% in the third quarter of 2025, selling 155,180 shares and leaving it with 1,613,121 shares valued at approximately $455.2 million. Despite this reduction, Amgen remains Pacer Advisors' ninth-largest holding. Amgen has reported strong financials, beating earnings estimates, setting positive FY2025 guidance, and increasing its quarterly dividend.
2025-12-26 08:53:55
Avanza Fonder AB increased its stake in Amgen Inc. by 8.6%, acquiring 4,546 shares to reach a total of 57,207 shares valued at $16.144 million. Amgen recently reported strong Q3 earnings, exceeding analyst estimates, and increased its quarterly dividend to $2.52 per share. Institutional ownership of Amgen stands at approximately 76.5%, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $332.85.
